AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE

INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH Pub Date : 2022-09-23 DOI:10.31069/japsr.v5i2.02

Nahid Rao, Reenoo Jauhari, Vaishali Sati, Pallavi Godiyal

{"title":"AN INSIGHT INTO THE TREATMENT STRATEGIES OF OBESITY USING SEMAGLUTIDE AND ITS COMPETITIVE ANALOGUES: A REVIEW ARTICLE","authors":"Nahid Rao, Reenoo Jauhari, Vaishali Sati, Pallavi Godiyal","doi":"10.31069/japsr.v5i2.02","DOIUrl":null,"url":null,"abstract":"Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.","PeriodicalId":13749,"journal":{"name":"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31069/japsr.v5i2.02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Obesity is a major public health problem in the world. This growing rate represents an epidemic that requires immediate attention. Oral Semaglutide is a semaglutide compound with an absorption enhancer, a sodium N- (8 - [2-hydroxybenzoyl] amino) caprylate (SNAC). The mechanism of action simply produces Glucagon-like peptide-1 (GLP-1) as a food-based digestive hormone that acts as an appetite signal, stimulates insulin release, inhibits glucagon production, and regulates diarrhea. This article shows the correlation of GLP-1 association with motivation to feed and Semaglutide’s anorectic effect and relation to cravings. We have performed complete searches from PubMed, Cochrane, Scopus, Medline, Medscape, and Wiley online library from 2015 to 2022. The trial data (SUSTAIN, PIONEER, STEP) suggested a major decrease in weight and HbA 1c. SELECT trial data showed cardiovascular safety of semaglutide over other anti-diabetic drugs. This review article summarized semaglutide trial data as an anti-obesity drug and compared the effects of semaglutide (oral and subcutaneous) with other GLP-1 analogs.

查看原文本刊更多论文

西马鲁肽及其竞争性类似物治疗肥胖症的研究综述

肥胖是世界上一个主要的公共卫生问题。这一不断增长的速度代表着一种需要立即予以关注的流行病。口服Semaglutide是一种具有吸收促进剂N-(8 -[2-羟基苯甲酰]氨基)辛酸钠(SNAC)的Semaglutide化合物。其作用机制只是产生胰高血糖素样肽-1 (GLP-1)，作为一种基于食物的消化激素，作为食欲信号，刺激胰岛素释放，抑制胰高血糖素的产生，并调节腹泻。这篇文章显示了GLP-1与进食动机和Semaglutide的厌食效果以及与渴望的关系的相关性。我们从2015年到2022年对PubMed、Cochrane、Scopus、Medline、Medscape和Wiley在线图书馆进行了完整的检索。试验数据(SUSTAIN, PIONEER, STEP)显示体重和HbA 1c显著降低。SELECT试验数据显示，西马鲁肽的心血管安全性优于其他抗糖尿病药物。这篇综述文章总结了西马鲁肽作为一种抗肥胖药物的试验数据，并比较了西马鲁肽(口服和皮下)与其他GLP-1类似物的效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH

自引率

0.00%

发文量